New price changes for Mounjaro – what they are, why they happened, and what the options are

We know price rises are the last thing you want to deal with when you’re working hard on your health. This update explains what’s changing, why it’s happening, and your options if you’re on treatment or thinking about starting.

What’s changing and what isn’t

• The private (non‑NHS) price of Mounjaro is going up across all doses.

• Wegovy and our other weight loss treatments aren’t affected.

• NHS pricing remains unchanged.

The new prices by dose

The new prices we’re offering for each Mounjaro dose are:

• 2.5 mg: £249

• 5 mg: £259

• 7.5 mg: £309

• 10 mg: £329

• 12.5 mg: £349

• 15 mg: £359

Nothing changes right away for existing customers. The new prices will only apply after 1st October, starting from your next renewal date. For example, if your subscription renews on 27 September, your new price won’t begin until 27 October.

You’re always in control. You’ll see the updated price for your dose in the app and at checkout before you confirm any order.

If you’d like to talk through your options, our clinical team is here to help - reach out anytime to discuss your plan. Your care and support remain our priority.

Why is the price going up?

When Mounjaro launched in the UK, the initial UK price was set lower than in many other countries. That helped:

• Speed up NHS access while global demand was high

• Make private access more affordable during early supply pressure

• Compete with alternatives like Wegovy

Eli Lilly is now aligning UK prices with other countries. This is a global pricing decision by the manufacturer, not a change driven by supply problems.

What stays the same

• Your clinical care and health coaching. We’ll keep your plan safe, evidence‑based, and tailored to you.

• Other treatments (including Wegovy) pricing. If you’re eligible, it remains an alternative at its current price.

• NHS costs. Patients receiving tirzepatide (Mounjaro) via the NHS are not affected by this private price change.

Your options with Numan

You can:

• Stay on your current Mounjaro dose.

• Adjust your dose (if clinically appropriate) to help manage cost and side effects.

• Switch to Wegovy if it is suitable for you.

• Stop medication and continue with behavioural and lifestyle changes.

If you’d like to switch or adjust your plan, submit a request in the app. A clinician will review your details and confirm next steps by email.

Thinking of switching?

• In most cases, you can start Wegovy one week after your last Mounjaro injection, unless your clinician advises otherwise.

• We’ll guide you on the safest start date and dose, and support you through the change.

If you’re affected by the new price

• Talk to us. Message your clinician in the app. We’re ready to support you, whether you decide to continue with Mounjaro, adjust your dose, switch to Wegovy, or take a break from GLP-1 medications altogether.

• For your safety, avoid unlicensed sellers. Buying from unauthorised sources is illegal and dangerous.

• Keep the foundations strong. Medication supports your progress, but lasting change comes from habits around food, movement, sleep, and stress. Connect with your health coach for tailored support to keep you motivated, help you tackle challenges, and celebrate every win. 

The numan take

Price changes are frustrating, but we promise to keep your care transparent and supportive. Whether you continue with Mounjaro, adjust your dose, or change your plan, we’ll help you choose a safe, effective plan that fits your goals and your budget.

References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., … STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

2. Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., … Vilsbøll, T. (2021). Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 75(2). doi:10.1111/ijcp.13731